A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic

  • Hildebrandt, Gerhard (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date1/8/20 → 9/30/22